Medication info

GC Arginine Injection (L-Arginine Hydrochloride)

Prescription medicationInjectionsOral · Intravenous injection
Ingredient · strength
L-Arginine Hydrochloride›0.6g / 1mL
Manufacturer / importer
Nokshipuja Wellbeing Co., Ltd.
Appearance
A colorless and transparent clear liquid filled in a colorless and transparent vial injection.
Packaging
10 milliliters/vial[x 10], 20 milliliters/vial[x 10], 25 milliliters/vial[x 10]
Approval status
Active

MFDS item code 201607169 · Notified 2016.12.19

Summary

Main use
Relief of hyperammonemia, pituitary function testing, and improvement of severe metabolic alkalosis
Who uses it
Adults
Adult dosage
Reduction of blood ammonia levels during acute exacerbations of hyperammonemia, only when control cannot be achieved with oral administration Administer 0.2~1g of L-arginine hydrochloride per kg of body weight by slow intravenous infusion over at least 1 hour. Acidifying agent for severe metabolic alkalosis Intravenous dose = L-arginine hydrochloride = desired decrease in plasma bicarbonate concentration (mM/L) × [patient's body weight (kg)/9.6] Pituitary function test for measuring growth hormone secretion Administer 500mg of L-arginine hydrochloride per kg of the subject's body weight as a 10% solution by slow intravenous infusion over at least 30 minutes.

Ingredients

Manufacturer
Nokshipuja Wellbeing Co., Ltd.

Efficacy & effects

Relief of hyperammonemia, pituitary function testing, and improvement of severe metabolic alkalosis

  • Hyperammonemia
  • congenital urea cycle disorders
  • lysinuric protein intolerance
  • severe metabolic alkalosis.
View approved original text

This drug is used to lower blood ammonia levels in cases of acute exacerbation of hyperammonemia caused by congenital urea cycle disorders and lysinuric protein intolerance, where oral administration is insufficient to control. It is also used as an acidifying agent in severe metabolic alkalosis and can be used instead of or in conjunction with the insulin-induced hypoglycemia test during pituitary function tests for growth hormone secretion measurement. However, this drug alone cannot establish a diagnosis, so it is important to conduct other tests alongside. This drug is effectively used for the treatment and improvement of the condition of the disease.

Dosage and Administration

Adult dosage

Reduction of blood ammonia levels during acute exacerbations of hyperammonemia, only when control cannot be achieved with oral administration Administer 0.2~1g of L-arginine hydrochloride per kg of body weight by slow intravenous infusion over at least 1 hour. Acidifying agent for severe metabolic alkalosis Intravenous dose = L-arginine hydrochloride = desired decrease in plasma bicarbonate concentration (mM/L) × [patient's body weight (kg)/9.6] Pituitary function test for measuring growth hormone secretion Administer 500mg of L-arginine hydrochloride per kg of the subject's body weight as a 10% solution by slow intravenous infusion over at least 30 minutes.

Precautions

This drug should not be used in patients with allergic reactions or hypersensitivity to this drug's components. Also, it should not be administered to patients with severe acidosis, hypotension, diseases related to nitric oxide production, patients with a history of myocardial infarction, and patients with arginine-degrading enzyme deficiency. Caution should be exercised in patients with severe liver dysfunction or moderate renal impairment, renal disease, or anuria, and patients with uremia or electrolyte imbalances also require careful monitoring. In patients with bronchial asthma, this drug may exacerbate symptoms, so caution is advised. Rapid administration of this drug may result in side effects such as nausea, vomiting, skin rash, headache, numbness, and venous irritation. Serious side effects such as hypotension, anaphylaxis, severe allergic reactions, and hyperkalemia have also been reported rarely. If an allergic reaction occurs during administration of this drug, antihistamines should be used, and blood pressure should be closely monitored during and for 24 hours after administration. Administration should be limited to patients with a confirmed diagnosis, and in suspected cases of congenital urea cycle disorders, careful use should be based on blood ammonia levels and symptoms. If hyperammonemia does not improve with this drug, additional treatments such as peritoneal dialysis, hemodialysis, or exchange transfusion may be required. Excessive administration of hydrochloride can lead to hyperchloremic acidosis, so acidity (pH) of the blood should be monitored during administration, and if acidosis is suspected, administration should be stopped and alkalinizing treatment should be provided. This drug may interact with spironolactone, so caution is advised when used together. It is advisable not to administer this drug to pregnant women or those who may become pregnant, and breastfeeding women should use it with caution. Overdosage may cause transient metabolic acidosis and hyperventilation, and treatment may be necessary to correct acidosis. No sufficient studies have been conducted regarding carcinogenicity, mutagenicity, or effects on reproductive ability with long-term use of this drug. During administration, there may be necrosis or ulceration of the skin at the injection site, so if redness, swelling, or pain occurs at the injection site, administration should be stopped immediately and appropriate treatment should be received. When stored, ensure that the solution does not discolor, cloud, or form precipitates, and do not use expired products or those with damaged packaging. Also, keep out of reach of children, and unused injection solution should not be reused.

Side effects

nausea, vomiting, erythema, headache, numbness, focal venous irritation, hypotension, anaphylactic reaction, severe allergic reaction, severe hyperkalemia, hypersensitivity, rash, urticaria, transient vomiting, skin necrosis, ulcer formation, erythema at the intravenous injection site, infiltration, swelling, transient metabolic acidosis, hyperventilation

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent exposure to air, and the storage temperature should be maintained at room temperature between 1 to 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

A colorless and transparent clear liquid filled in a colorless and transparent vial injection.

Package unit

10 milliliters/vial[x 10], 20 milliliters/vial[x 10], 25 milliliters/vial[x 10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.